Targeted Oncology40m
Emerging Data on Oral SERDS
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective ...
Targeted Oncology51m
EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...
Targeted Oncology50m
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 ...
Targeted Oncology55m
Co-occurrence of ESR1m with other alterations
Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and ...